242 studies found for:    "Expanded Access" [STUDY-TYPES]
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Approved for marketing Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease
Condition: Multiple Myeloma
Intervention: Drug: Carfilzomib
2 Available PFO ACCESS Registry
Conditions: Patent Foramen Ovale;   Stroke
Intervention: Device: Device closure with the AMPLATZER PFO Occluder
3 Temporarily not available Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Erlotinib
4 Available Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination
Conditions: Toxicity Due to Chemotherapy;   Impaired 5FU Elimination
Intervention: Drug: uridine triacetate
5 Available Post Study Continuation of C7 for G1D
Conditions: Glut1 Deficiency Syndrome;   Glucose Transporter Type 1 Deficiency Syndrome
Intervention: Drug: Triheptanoin
6 No longer available This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.
Conditions: Non-Hodgkin's Lymphoma;   Hodgkin's Disease;   Multiple Myeloma
Intervention: Drug: Plerixafor
7 Approved for marketing BMN 110 US Expanded Access Program
Conditions: Mucopolysaccharidosis IVA;   Morquio A Syndrome;   MPS IVA
Intervention: Drug: BMN 110
8 No longer available Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental Exposure
Condition: West Nile Virus Infection
Intervention: Biological: MGAWN1
9 Available Compassionate Use of Triheptanoin (C7) for Fatty Acid Oxidation Disorders and Glycogen Storage Disease
Conditions: Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency;   Carnitine Palmitoyltransferase Deficiencies (CPT1, CPT2);   Mitochondrial Trifunctional Protein Deficiency;   Long-chain Hydroxyacyl-CoA Dehydrogenase Deficiency;   Glycogen Storage Disorders;   Pyruvate Carboxylase Deficiency, Type B;   Acyl-coA Dehydrogenase, Type 9
Intervention: Drug: triheptanoin
10 No longer available An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.
Condition: HIV Infections
Intervention: Drug: Tipranavir
11 Available Use Massive Parallel Sequencing and Exome Capture Technology to Sequence the Exome of Fanconi Anemia Children and Their Patents
Conditions: Fanconi Anemia;   Autosomal or Sex Linked Recessive Genetic Disease;   Bone Marrow Hematopoiesis Failure, Multiple Congenital Abnormalities, and Susceptibility to Neoplastic Diseases.;   Hematopoiesis Maintainance.
Interventions: Genetic: human whole exome;   Genetic: whole genomic
12 No longer available Stiripentol in Dravet Syndrome
Condition: Dravet Syndrome
Intervention: Drug: stiripentol
13 Available Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Afatinib
14 Approved for marketing Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis
Conditions: Cystic Fibrosis;   Pseudomonas Aeruginosa
Intervention: Drug: Aztreonam lysine
15 No longer available Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
Conditions: Major Depressive Disorder;   Fibromyalgia;   Diabetic Peripheral Neuropathic Pain;   Generalized Anxiety Disorder
Intervention: Drug: Duloxetine Hydrochloride
16 Approved for marketing A Treatment-Option Study of Brentuximab Vedotin in Patients With Progression of Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
17 Unknown  Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy
Condition: Multiple Myeloma
Intervention: Drug: Bortezomib/Dexamethasone/Melphalan
18 Available Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
Condition: Non-small Cell Lung Cancer (NSCLC)
Intervention: Drug: LDK378
19 Approved for marketing Expanded Access of Cabozantinib in Medullary Thyroid Cancer
Condition: Medullary Thyroid Cancer
Intervention: Drug: cabozantinib
20 Available Bivalirudin foR Acute Myocardial Infarction underGoing Angioplasty in CHinese patienTs.
Condition: Acute Myocardial Infarction
Intervention: Drug: Bivalirudin

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years